TY - JOUR
T1 - Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome
T2 - a systematic review and meta-analysis
AU - Shim, Sung Ryul
AU - Cho, Young Joo
AU - Shin, In Soo
AU - Kim, Jae Heon
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media Dordrecht.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose: To investigate the overall treatment efficacy and safety of botulinum toxin type A (BoNTA) injections compared with placebo in interstitial cystitis/bladder pain syndrome (IC/BPS). Methods: We conducted a systematic review and meta-analysis of the published literature in PubMed, Cochrane Library, and EMBASE on BoNTA use in IC/BPS. Outcome measures included changes of OLS, ICSI, ICPI, VAS, frequency, nocturia, FBC, Qmax, and PVR from baseline and also included adverse events. Results: A total of five studies were included, with a total sample size of 252 subjects (133 subjects in the experimental group and 119 subjects in the control group). The duration of follow-up ranged from 8 to 12 weeks. The BoNTA dosage was from 50 to 200 U. The pooled overall SMD in the mean change of VAS for the BoNTA group versus the placebo group was −0.49 (95 % CI −0.74, −0.23). There were also significant improvements in ICPI and frequency. The other outcomes (ICSI, nocturia, Qmax, and FBC) were not statistically different between the two groups. Conclusion: Although BoNTA is not regulatory approved indication, this first evidence-based systematic review and meta-analysis of BoNTA injection for IC/BPS showed significant differences in efficacy of treatment compared with placebo, especially for pain control, and also showed no differences in the rate of procedure-related adverse events.
AB - Purpose: To investigate the overall treatment efficacy and safety of botulinum toxin type A (BoNTA) injections compared with placebo in interstitial cystitis/bladder pain syndrome (IC/BPS). Methods: We conducted a systematic review and meta-analysis of the published literature in PubMed, Cochrane Library, and EMBASE on BoNTA use in IC/BPS. Outcome measures included changes of OLS, ICSI, ICPI, VAS, frequency, nocturia, FBC, Qmax, and PVR from baseline and also included adverse events. Results: A total of five studies were included, with a total sample size of 252 subjects (133 subjects in the experimental group and 119 subjects in the control group). The duration of follow-up ranged from 8 to 12 weeks. The BoNTA dosage was from 50 to 200 U. The pooled overall SMD in the mean change of VAS for the BoNTA group versus the placebo group was −0.49 (95 % CI −0.74, −0.23). There were also significant improvements in ICPI and frequency. The other outcomes (ICSI, nocturia, Qmax, and FBC) were not statistically different between the two groups. Conclusion: Although BoNTA is not regulatory approved indication, this first evidence-based systematic review and meta-analysis of BoNTA injection for IC/BPS showed significant differences in efficacy of treatment compared with placebo, especially for pain control, and also showed no differences in the rate of procedure-related adverse events.
KW - Bladder pain syndrome
KW - Botulinum toxin
KW - Interstitial cystitis
KW - Meta-analysis
KW - Placebo
UR - http://www.scopus.com/inward/record.url?scp=84965025461&partnerID=8YFLogxK
U2 - 10.1007/s11255-016-1295-y
DO - 10.1007/s11255-016-1295-y
M3 - Article
C2 - 27139498
AN - SCOPUS:84965025461
SN - 0301-1623
VL - 48
SP - 1215
EP - 1227
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 8
ER -